Cogent Biosciences (COGT) News
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.72-1.02 (-3.70%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
COGT news summary
We found 5 recent headlines mentioning Cogent Biosciences (COGT): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. For price context, COGT is down 3.70% at $26.72. The most recent story, "Cogent Biosciences reports Q3 results", was published by Seeking Alpha on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Cogent Biosciences headlines
- Cogent Biosciences reports Q3 resultsSeeking Alpha
- Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial ResultsPreparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027GlobeNewswire
- Biotech Stocks Facing FDA Decision In November 2026(RTTNews) - The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.NasdaqAGIO, BBIO, CAPR, COGT
- Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation ConferenceWALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined…GlobeNewswire
- Cogent Biosciences Enters Oversold Territory (COGT)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq